Carregant...
A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs
BACKGROUND: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. OBJECTIVE: To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IF...
Guardat en:
| Publicat a: | Mult Scler J Exp Transl Clin |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299291/ https://ncbi.nlm.nih.gov/pubmed/30574342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318819031 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|